The sigmoid take-off as a landmark to distinguish rectal from sigmoid tumours on MRI: Reproducibility, pitfalls and potential impact on treatment stratification.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 01 07 2021
revised: 10 09 2021
accepted: 13 09 2021
pubmed: 30 9 2021
medline: 22 2 2022
entrez: 29 9 2021
Statut: ppublish

Résumé

The sigmoid take-off (STO) was recently introduced as a preferred landmark, agreed upon by expert consensus recommendation, to discern rectal from sigmoid cancer on imaging. Aim of this study was to assess the reproducibility of the STO, explore its potential treatment impact and identify its main interpretation pitfalls. Eleven international radiologists (with varying expertise) retrospectively assessed n = 155 patients with previously clinically staged upper rectal/rectosigmoid tumours and re-classified them using the STO as completely below (rectum), straddling the STO (rectosigmoid) or completely above (sigmoid), after which scores were dichotomized as rectum (below/straddling STO) and sigmoid (above STO), being the clinically most relevant distinction. A random subset of n = 48 was assessed likewise by 6 colorectal surgeons. . Interobserver agreement (IOA) for the 3-category score ranged from κ0.19-0.82 (radiologists) and κ0.32-0.72 (surgeons), with highest scores for the most experienced radiologists (κ0.69-0.76). Of the 155 cases, 44 (28%) were re-classified by ≥ 80% of radiologists as sigmoid cancers; 36 of these originally received neoadjuvant treatment which in retrospect might have been omitted if the STO had been applied. Main interpretation pitfalls were related to anatomical variations, borderline cases near the STO and angulation of axial imaging planes. Good agreement was reached for experienced radiologists. Despite considerable variation among less-expert readers, use of the STO could have changed treatment in ±1/4 of patients in our cohort. Identified interpretation pitfalls may serve as a basis for teaching and to further optimize MR protocols.

Identifiants

pubmed: 34583878
pii: S0748-7983(21)00735-6
doi: 10.1016/j.ejso.2021.09.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-244

Investigateurs

Femke Alberts (F)
Frans C H Bakers (FCH)
Nino Batiashvili (N)
Geerard L Beets (GL)
Regina G H Beets-Tan (RGH)
Shira de Bie (S)
Nino Bogveradze (N)
Gerlof Bosma (G)
Vincent C Cappendijk (VC)
Francesca Castagnoli (F)
Ana Daushvili (A)
Pascal Doornebosch (P)
Raphaëla C Dresen (RC)
Remy Geenen (R)
Brechtje Grotenhuis (B)
Tedo Jokharidze (T)
Najim El Khababi (N)
Miranda Kusters (M)
Max J Lahaye (MJ)
Doenja M J Lambregts (DMJ)
Federica Landolfi (F)
Marjolein Leeuwenburgh (M)
Monique Maas (M)
Peter Neijenhuis (P)
Gerald Peterson (G)
Ernst J A Steller (EJA)
Cornelis J Veeken (CJ)
Pieter J Tanis (PJ)
Sofie De Vuysere (S)
Maarten Vermaas (M)
Roy F A Vliegen (RFA)
Albert Wolthuis (A)

Informations de copyright

Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nino Bogveradze (N)

Dept. of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; GROW School for Oncology & Developmental Biology, University of Maastricht, Maastricht, the Netherlands; Dept. of Radiology, Acad. F. Todua Medical Center, Research Institute of Clinical Medicine, Tbilisi, Georgia.

Doenja M J Lambregts (DMJ)

Dept. of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Najim El Khababi (N)

Dept. of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; GROW School for Oncology & Developmental Biology, University of Maastricht, Maastricht, the Netherlands.

Raphaëla C Dresen (RC)

Dept. of Radiology, University Hospitals Leuven, Leuven, Belgium.

Monique Maas (M)

Dept. of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Miranda Kusters (M)

Dept. of Surgery, Amsterdam University Medical Centres, Cancer Centre Amsterdam, the Netherlands.

Pieter J Tanis (PJ)

Dept. of Surgery, Amsterdam University Medical Centres, Cancer Centre Amsterdam, the Netherlands.

Regina G H Beets-Tan (RGH)

Dept. of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; GROW School for Oncology & Developmental Biology, University of Maastricht, Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH